Market Data
Market Cap₹16,790.42 Cr.
52W High₹998
Current Price₹854.2
52W Low₹635.3
Down from 52W High14.4 %
Face Value₹2
Performance
ROCE11.7 %
ROE12.22 %
EPS (TTM)₹8.8
EPS Prev Qtr₹10.31
EPS Last Year₹9.4
EBITDA Qtr₹234.15 Cr.
Book Value₹289
Financial Health
Debt/Equity0.24
Debt/Profit1.97
Total Assets₹8,762.58 Cr.
Dividend Yield1.4 %
Promoter Holding69.87 %
Earning Power9.43 %
Valuation
Stock P/E24.22
Industry P/E33.81
Price to Book2.96
Price to Sales2.16
Graham Number₹478.55
Key Metrics
Debt/Equity
0.22
Face Value
₹2
Interest Coverage
9.04
About Alembic Pharmaceuticals Ltd
Healthcare · Pharmaceuticals
Alembic Pharmaceuticals Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹16,790.42 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a healthy promoter holding of 69.87%, indicating strong control and alignment of interests.
- The company maintains a conservative capital structure with a Debt to Equity ratio of 0.24, suggesting lower financial risk.
- The Interest Coverage ratio of 9.04 demonstrates the company's strong ability to meet its interest obligations.
- The company has generated a Net Profit of ₹689.55 Cr on a Revenue of ₹7783.95 Cr, indicating reasonable profitability.
Weaknesses
- The P/E Ratio of 23.03 may indicate that the stock is relatively expensive compared to its earnings.
- The P/B Ratio of 2.81 suggests that the market values the company at a premium over its book value.
- The Dividend Yield of 1.48% is relatively low, indicating limited income potential for investors.
- The ROCE of 11.7% and ROE of 12.15% indicate moderate efficiency in generating returns on capital and equity, respectively.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 1,910.15 | 1,876.31 | 1,847.72 | 2,149.77 |
| ↳ QoQ Growth | - | -1.8% | -1.5% | +16.3% |
| Expenses | 1,670.53 | 1,662.93 | 1,708.39 | 1,915.62 |
| Operating Profit | 239.62 | 213.38 | 139.33 | 234.15 |
| OPM % | 12.54% | 11.37% | 7.54% | 10.89% |
| Other Income | 6.91 | 15.5 | 25.5 | 14.93 |
| Interest | 24.23 | 23.31 | 22.56 | 27.61 |
| Depreciation | 76.07 | 80.12 | 88.59 | 97.71 |
| EBITDA | 315.69 | 293.5 | 227.92 | 331.86 |
| EBITDA Margin % | 16.53% | 15.64% | 12.34% | 15.44% |
| Profit Before Tax | 223.72 | 161.5 | 118.62 | 221.86 |
| Tax % | 17.88% | 18.3% | -69.9% | 22.31% |
| Net Profit | 183.71 | 131.95 | 201.53 | 172.36 |
| ↳ QoQ Growth | - | -28.2% | +52.7% | -14.5% |
| EPS | 9.4 | 6.76 | 10.31 | 8.8 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 39.31 | 39.31 |
| Reserves | 5151.63 | 5635.5 |
| Borrowings | 1257.5 | 1360.85 |
| Other Liabilities | 1324.5 | 1726.92 |
| Total Liabilities | 7772.94 | 8762.58 |
| Fixed Assets | 2523.53 | 3130.37 |
| CWIP | 837.23 | 633.7 |
| Investments | 127.21 | 140.88 |
| Other Assets | 4284.97 | 4857.63 |
| Total Assets | 7772.94 | 8762.58 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 782.73 |
| Cash from Investing Activity | -506.06 |
| Cash from Financing Activity | -163.78 |
| Net Cash Flow | 112.89 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 69.74% | 69.74% | 69.74% | 69.87% |
| FIIs % | 4.05% | 4.24% | 4.25% | 4.18% |
| DIIs % | 16.3% | 16.17% | 16.18% | 15.94% |
| Public % | 6.93% | 6.87% | 6.86% | 6.97% |
| No. of Shareholders | 89,969 | 87,000 | 86,432 | 86,796 |
Major Shareholders (>1%)
- Nirayu Private LimitedPromoter and Promoter Group35.78%
- Alembic LimitedPromoter and Promoter Group28.54%
- Life Insurance Corporation Of IndiaPublic Shareholding4.32%
- Dsp Small Cap FundPublic Shareholding3.86%
As of 2026-06-30View all shareholders →